NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has given conditional approval for the company's Rosetta Kidney Cancer Test for patient samples originating from New York.

As a result of the conditional approval, the test is now available in all 50 states in the US. However, Rosetta will have to provide any additional information within 60 business days to NYDOH as requested as part of the conditional approval, the Israel-based developer of microRNA-based molecular diagnostics tests said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.